ERBB2 and breast cancer: Lapatinib, an oral reversible tyrosine kinase inhibitor that blocks both ErbB1 and ErbB2, crossed the blood-brain barrier, and combined with capecitabine resulted in partial and complete responses of BM from HER-2 positive breast cancers [56].